Bio-Rad Laboratories, Inc. (BIO)
After hours:
| Previous close | 315.17 |
| Open | 316.10 |
| Bid | 319.78 x 900 |
| Ask | 355.00 x 1200 |
| Day's range | 313.95 - 322.99 |
| 52-week range | 261.59 - 426.74 |
| Volume | |
| Avg. volume | 257,178 |
| Market cap | 9.004B |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.68 |
| Earnings date | 01 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 343.40 |
Insider MonkeyBio-Rad Laboratories’ (BIO) Growth Tailwinds Are Delayed, Not Derailed
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -6.31% in the second quarter, compared to S&P’s 4.28% return and Russell 1000 Value’s -2.17% return. There weren’t enough big winners in the portfolio, and the relative performance […]
ZacksBio-Rad (BIO) to Report Q2 Earnings: What's in the Cards?
Within Bio-Rad's (BIO) Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely impacted sales.
Business WireBio-Rad to Report Second Quarter Financial Results on Thursday, August 1, 2024
HERCULES, Calif., July 17, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2024 on Thursday, August 1, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
